156 related articles for article (PubMed ID: 38265498)
1. C-5401331 identified as a novel T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) inhibitor to control acute myeloid leukemia (AML) cell proliferation.
Al Shahrani M; Gahtani RM; Makkawi M
Med Oncol; 2024 Jan; 41(3):63. PubMed ID: 38265498
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening.
Abdel-Rahman SA; Talagayev V; Pach S; Wolber G; Gabr MT
J Med Chem; 2023 Aug; 66(16):11464-11475. PubMed ID: 37566998
[TBL] [Abstract][Full Text] [Related]
3. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract][Full Text] [Related]
4. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
5. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
6. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
7. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.
Wang Z; Chen J; Wang M; Zhang L; Yu L
Front Immunol; 2021; 12():618710. PubMed ID: 33868234
[TBL] [Abstract][Full Text] [Related]
8. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
Wang J; Yang L; Dao FT; Wang YZ; Chang Y; Xu N; Chen WM; Jiang Q; Jiang H; Liu YR; Qin YZ
Leuk Lymphoma; 2022 Jan; 63(1):152-161. PubMed ID: 34405769
[TBL] [Abstract][Full Text] [Related]
10. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
11. TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1.
Shapourian H; Ghanadian M; Eskandari N; Shokouhi A; Demirel GY; Bazhin AV; Ganjalikhani-Hakemi M
BMC Cancer; 2024 Jan; 24(1):125. PubMed ID: 38267906
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
[TBL] [Abstract][Full Text] [Related]
13. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract][Full Text] [Related]
14. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
Kikushige Y
Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.
Wu Z; Ou J; Liu N; Wang Z; Chen J; Cai Z; Liu X; Yu X; Dai M; Zhou H
Cancer Med; 2023 Apr; 12(7):8956-8969. PubMed ID: 36545697
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
[TBL] [Abstract][Full Text] [Related]
18. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia.
Tan J; Huang S; Huang J; Yu Z; Chen Y; Lu Y; Li Y; Chen S
Asia Pac J Clin Oncol; 2020 Jun; 16(3):137-141. PubMed ID: 32030888
[TBL] [Abstract][Full Text] [Related]
19. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.
Gonçalves Silva I; Gibbs BF; Bardelli M; Varani L; Sumbayev VV
Oncotarget; 2015 Oct; 6(32):33823-33. PubMed ID: 26413815
[TBL] [Abstract][Full Text] [Related]
20. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Rakova J; Truxova I; Holicek P; Salek C; Hensler M; Kasikova L; Pasulka J; Holubova M; Kovar M; Lysak D; Kline JP; Racil Z; Galluzzi L; Spisek R; Fucikova J
Oncoimmunology; 2021 Mar; 10(1):1889822. PubMed ID: 33758676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
